Tag: ASX:IDT
IDT Australia secures $3.2M manufacturing contract for investigational eye therapy
ASX-listed IDT Australia Limited has been awarded a five-year contract valued at $3.2 million for the manufacture of NPI-001 tablets, an investigational treatment for retinitis pigmentosa (RP), a degenerative eye disease that can lead to vision loss.
Featured Article
Responding to manufacturing demand and performance signals
Australian manufacturers are navigating a challenging environment. Just as output had returned to growth, higher fuel and freight costs, rising input prices and global supply chain disruption renewed pressure on margins and cash flow.
